Sichenzia Ross Friedman Ference LLP Advises Can-Fite Biopharmaceuticals on Multi-Million Dollar Licensing Agreement with Cipher Pharmaceuticals
Sichenzia Ross Friedman Ference LLP Advises Can-Fite Biopharmaceuticals on Multi-Million Dollar Distribution Agreement with Cipher Pharmaceuticals
New York – April 1, 2015 – Securities and Corporate law firm Sichenzia Ross Friedman Ference LLP has announced today that the Firm represented Can-Fite Biopharmaceuticals Ltd., (NYSE MKT: CANF) an Israeli biopharmaceutical company developing therapeutic products, in a multi million dollar Distribution Agreement where Cipher Pharmaceuticals, Inc. will distribute Can-Fite’s leading drug candidate, CF101 in the Canadian market for certain indications upon receipt of regulatory approval.
The Sichenzia Ross Friedman Ference LLP team was led by Partner Greg Sichenzia and Gary Emmanuel.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents HiVentures Zrt., a Hungarian Venture Capital Company, in Private Placement of Series A Preferred Stock of ActiveGraf - January 16, 2020
- Trusts and Estates Attorney - January 13, 2020
- Sichenzia Ross Ference LLP Represents A.G.P./Alliance Global Partners as Sole Placement Agent in $3M Registered Direct Offering of Cellect Biotechnology Ltd. - January 10, 2020